Observational studyDiabetes, obesity & metabolism2026
Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex.
Observational study in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex.Diabetes, obesity & metabolism · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOlder adults with type 2 diabetes (T2DM) are less likely to receive sodium-glucose cotransporter-2 (SGLT2) inhibitors, despite their proven cardio-renal benefits and safety. Whether this age-related gap is driven by frailty, sex, or other factors remains unclear.
methodsThis observational study analysed data from adults registered in primary care during 2023, using the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database. Eligibility for SGLT2 inhibitor treatment was determined based on the Dutch College of General Practitioners (NHG) guideline for T2DM. Prescription rates were assessed across demographics, comorbidities, and preceding medication use. Multivariable logistic regression models were used to assess the association of age and identify factors associated with SGLT2 inhibitor prescriptions.
resultsAmong 10 241 adults with T2DM, 41% (n = 4223) were eligible for SGLT2 inhibitor prescription. The prescription rate in the overall population was 15.2% and among eligible people was 25.5%. In people eligible for SGLT2 inhibitors, prescription rates were markedly lower with increasing age, with 37.6% in those aged <60 years, 32.1% in 60-69 years, 27.2% in 70-79 years, and only 13.7% in those aged ≥80 years. In multivariable analysis, compared with those aged <60 years, individuals aged 70-79 and ≥80 were associated with significantly decreased likelihood of SGLT2 inhibitor prescription, independent of frailty and other relevant covariates [odds ratio (OR): 0.56, 95%CI: 0.43-0.72] and (OR: 0.22, 95%CI: 0.16-0.30), respectively. Age disparities in SGLT2 inhibitor prescription were evident across subgroups, including different levels of frailty and both sexes, with disparities particularly pronounced in females compared with males (p
conclusionsSGLT2 inhibitor prescription rates among Dutch adults with T2DM were low, with persistent age- and sex-related disparities independent of frailty, highlighting the need for equitable prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.